Qin Wei, Xu Xiao-Kang, Wang Yao, Meng Xiang-Mei, Yang Cheng-Wu, Xia Feng, Su Hong
Department of Expanded Program on Immunization, Lu'an Municipal Center for Disease Control and Prevention , Lu'an, Anhui, China.
Department of Expanded Program on Immunization, Huoshan County Center for Disease Control and Prevention , Lu'an, Anhui, China.
Hum Vaccin Immunother. 2020 Aug 2;16(8):1851-1856. doi: 10.1080/21645515.2019.1704574. Epub 2020 Mar 2.
Although a varicella vaccine has been available in China since 1998 in the private sector, varicella outbreaks and breakthrough varicella (BV) still occur. In 2018, four varicella outbreaks with high BV rate sequentially occurred in four schools in Lu'an, sparking local public health authority's concerns on the varicella vaccine. Therefore, we conducted this investigation to evaluate varicella vaccine effectiveness (VE), characterize BV, and detect potential risk factors associated with BV.
This was a three-stage study. First, a retrospective cohort study was done in each school to estimate the VEs of varicella vaccine during outbreaks. Second, a descriptive epidemiological method was used to describe the characteristics of the four outbreaks and to compare the clinical characteristics between the BV cases and unvaccinated varicella cases. To identify the risk factors associated with BV, we conducted an unmatched case-control study in the third stage of the study.
A total of 199 cases were identified among four outbreaks, and the overall attack rate was 14%. Of 1203 students with available vaccination information, 822 (68%) were vaccinated at least once. The overall VEs among four outbreaks ranged from 19% to 69%, whereas the VE against moderate or severe varicella ranged from 74% to 90%. Compared with unvaccinated varicella cases, the moderate or severe varicella ( < .001) and fever ( = .029) in the BV group were less common. Besides, BV cases had a shorter duration of disease ( = .007). Children vaccinated more than six years before the outbreak had a higher risk of developing BV compared with those vaccinated within the past six years (OR = 2.4, 95% CI: 1.2-4.8). The risk of developing BV differed by the exposure intensity. Compared with the presence of three or fewer varicella cases in the same class, the OR was 7.8 (95% CI: 3.6-16.9) for four to nine cases in the same class and 25.2 (95% CI: 13.5 -47.2) for that of 10 or more cases.
The overall VE was insufficient to protect varicella infection, and the VE for moderate or severe varicella was only moderate. The manifestations of BV cases were generally milder than those seen in natural varicella infection. The time since vaccination and the intensity of exposure are risk factors for developing BV during an outbreak.
尽管自1998年以来中国私营部门就有了水痘疫苗,但水痘疫情和突破性水痘(BV)仍时有发生。2018年,六安市四所学校相继发生四起水痘疫情,BV发生率较高,引发了当地公共卫生部门对水痘疫苗的关注。因此,我们开展了此次调查,以评估水痘疫苗效力(VE)、描述BV特征并检测与BV相关的潜在风险因素。
这是一项分三个阶段的研究。首先,在每所学校进行回顾性队列研究,以估计疫情期间水痘疫苗的VE。其次,采用描述性流行病学方法描述四起疫情的特征,并比较BV病例与未接种疫苗的水痘病例的临床特征。为了确定与BV相关的风险因素,我们在研究的第三阶段进行了非匹配病例对照研究。
四起疫情中共确诊199例病例,总罹患率为14%。在1203名有疫苗接种信息的学生中,822名(68%)至少接种过一次疫苗。四起疫情的总体VE在19%至69%之间,而针对中度或重度水痘的VE在74%至90%之间。与未接种疫苗的水痘病例相比,BV组中中度或重度水痘(<0.001)和发热(=0.029)的情况较少见。此外,BV病例的病程较短(=0.007)。与在疫情发生前六年内接种疫苗的儿童相比,在疫情发生前六年以上接种疫苗的儿童发生BV的风险更高(OR=2.4,95%CI:1.2-4.8)。发生BV的风险因接触强度而异。与同一班级中有三例或更少水痘病例的情况相比,同一班级中有四至九例水痘病例时的OR为7.8(95%CI:3.6-16.9),有10例或更多水痘病例时的OR为25.2(95%CI:13.5-47.2)。
总体VE不足以预防水痘感染,对中度或重度水痘的VE仅为中等水平。BV病例的表现通常比自然感染水痘时的表现更轻。接种疫苗后的时间和接触强度是疫情期间发生BV的风险因素。